GlassScriptPhysician profile
Matthew D Williams
NPI 1144749359
$2,204.01
in general payments reported to CMS, 2019-2025
34 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $288 · 2023: $450 · 2024: $682 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.77 |
| Education | $167.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $348.19 | 2022-2024 | Jaypirca, Retevmo, Verzenio |
| E.R. Squibb & Sons, L.L.C. | $273.12 | 2021-2025 | Opdivo, Eliquis |
| Aveo Pharmaceuticals, INC. | $144.67 | 2023-2024 | Fotivda |
| Secura Bio, INC. | $144.12 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.57 | 2024-2025 | Imfinzi, Lynparza |
| Janssen Pharmaceuticals, INC | $123.73 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $116.86 | 2023 | Libtayo |
| Janssen Biotech, INC. | $97.22 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Merck Sharp & Dohme LLC | $72.72 | 2024-2025 | Keytruda, Lynparza |
| Beone Medicines USA, INC. | $57.29 | 2025 | Brukinsa, Tevimbra |
| Menarini Silicon Biosystems, INC. | $53.03 | 2025 | Cellsearch |
| Daiichi Sankyo INC. | $51.81 | 2022-2025 | Datroway |
| Incyte Corporation | $49.56 | 2022-2024 | Jakafi |
| Genmab U.S., INC. | $49.41 | 2023-2025 | Epkinly, Tivdak |
| Karyopharm Therapeutics INC. | $45.82 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $41.82 | 2023-2024 | |
| Eisai INC. | $38.12 | 2024-2025 | |
| Genentech USA, INC. | $33.06 | 2025 | Polivy, Tecentriq |
| Abbvie INC. | $32.61 | 2023-2025 | |
| Foundation Medicine, INC. | $32.57 | 2022 | |
| Tempus Ai, INC | $29.98 | 2024 | |
| Caris Mpi, INC. | $29.23 | 2025 | Mi Cancer Seek |
| Genzyme Corporation | $25.73 | 2023 | |
| Adaptive Biotechnologies Corporation | $21.29 | 2025 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.50 | 2025 | Onivyde |
| Novartis Pharmaceuticals Corporation | $17.64 | 2023 | |
| Geron Corporation | $16.62 | 2025 | Rytelo |
| Seagen INC. | $16.60 | 2023 | Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $16.54 | 2023 | Imbruvica, Epkinly |
| Cumberland Pharmaceuticals, INC. | $16.11 | 2023 | Sancuso |
| Cti Biopharma Corp. | $14.88 | 2023 | Vonjo |
| Servier Pharmaceuticals LLC | $14.79 | 2023 | |
| Glaxosmithkline, LLC. | $14.60 | 2024 | Zejula, Jemperli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.